Ormaplatin resistance is associated with decreased accumulation of its platinum (II) analogue, dichloro(D,L-trans)1,2-diaminocyclohexaneplatinum(II)
1996

Ormaplatin Resistance and Drug Accumulation

publication Evidence: moderate

Author Information

Author(s): D Rischin, V Ling

Primary Institution: The Ontario Cancer Institute, Princess Margaret Hospital

Hypothesis

Cross-resistance to ormaplatin is associated with decreased accumulation of its platinum analogue PtCl2(trans-dach).

Conclusion

Cisplatin-resistant cell lines show cross-resistance to ormaplatin, linked to energy-dependent decreased accumulation of PtCl2(trans-dach).

Supporting Evidence

  • Ormaplatin is converted to PtCl2(trans-dach) in tissue culture media.
  • Cisplatin-resistant cell lines show decreased accumulation of PtCl2(trans-dach).
  • Energy metabolism inhibitors increased drug accumulation in resistant cells.
  • Extracellular thiol concentration affects the reduction of ormaplatin.

Takeaway

Some cancer cells that resist a drug called cisplatin also resist a similar drug called ormaplatin because they don't take in the drug as well when they don't have enough energy.

Methodology

The study used murine lymphoma cell lines to assess drug resistance and accumulation through various assays including MTT and HPLC.

Limitations

The study primarily focuses on specific cell lines and may not generalize to all cancer types.

Participant Demographics

Murine lymphoma cell lines, specifically E8 and E5.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication